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Abstract
Background: Urinary creatinine can be quantified by Jaffe or enzymatic assays and is commonly used as denominator
of urinary excretion of electrolytes or protein. Paired analysis in pediatric and adult samples documented inter-assay
differences (up to 80%). We verified the interchangeability of two IDMS-traceable assays (Jaffe and enzymatic) for
neonatal urine and report on neonatal urinary creatinine values using these IDMS-traceable methods.
Methods: Creatinine was measured in 84 neonatal urine samples from 46 neonates by an IDMS traceable Jaffe and
enzymatic assay (Roche Diagnostics, Cobas c702 module). Creatinine values, differences in urinary creatinine and clinical
characteristics were described and covariates of between assay difference were explored (Wilcoxon, Bland-Altman,
correlation, multiple regression).
Results: Median Jaffe and enzymatic urinary creatinine concentrations were 9.25 (range 3.7-42.2) and 9.15
(range 3.8-42.9) mg/dL respectively, resulting in a median difference of 0.08 (SD 0.6, range −2.4 to 0.96) mg/dL. In a
multiple regression model, urinary enzymatic creatinine concentration (r = 0.45) and postnatal age (r = −0.59) remained
independent variables of the difference between both assays (r2 adj = 0.45).
Conclusions: The tested IDMS-traceable assays showed interchangeable in heterogeneous neonatal urine samples.
Using these assays, neonatal urinary creatinine showed 5–20 fold lower values than those observed in children or adults
with a significant negative correlation with postnatal age.
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Background
Assessment of renal function includes glomerular filtra-
tion rate (GFR) and renal tubular transport activities.
This necessitates quantification of urinary creatinine, ei-
ther to calculate creatinine clearance as GFR estimate
or as denominator to quantify renal tubular activities
(e.g. sodium, potassium, amino acids, proteins, calcium,
phosphate, glucose) [1,2]. However, neonates have a
lower muscular mass resulting in lower creatinine syn-
thesis. They also display extensive maturational changes
in GFR. Both phenomena result in significantly lower
median urine creatinine concentrations (9.7 mg/dL) [2]
compared to observations in children (50 mg/dL) [3] or
adults (154 and 269 mg/dL) [4,5]. In addition, tubular
maturation initially results in renal wasting of small sol-
utes and a more limited urinary pH range while diuresis
increases in the first days or weeks of life [1,6]. Finally,
changes in renal elimination of conjugated bilirubin occur
secondary to age-related glucuronidation capacity [6].
For accurate and interchangeable test results adequate
standardization is of utmost importance. Historically,
creatinine assays showed great variation depending on
reaction mechanism (Jaffe or enzymatic reaction) and
manufacturer. Consequently, expected creatinine values
in neonates depended on the specific method used.
IDMS-traceable creatinine assays have been introduced
to solve this problem [7]. The IDMS re-calibration is,
however, more extensively verified for serum than urine
matrix by the manufacturer (internal communication
with Roche Diagnostics). This standardization also does
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not eliminate differences related to the reaction mechan-
ism. Jaffe methods display interference by endogenous
(e.g. pseudocreatinines, bilirubin, glucose) and exogen-
ous (e.g. cefalosporins) substances. Although enzymatic
methods are less prone, these assays can also be affected
by interferences (e.g. bilirubin, dopamine) [8-10]. Due to
the above-mentioned maturational changes and frequent
medication use, the composition of neonatal urine is
variable and different from adults. Given the method spe-
cific interferences, urinary creatinine may still vary in an
method and assay specific way with between assay dif-
ferences related to the composition of neonatal urine. Dif-
ferences up to 80% have been describes in children
comparing Jaffe and enzymatic assays, with median urin-
ary concentrations of 69 to 75 mg/dL depending on the
method applied [3]. Taking above-mentioned remarks
into account, the interchangeability of two IDMS-
traceable assays (Jaffe and enzymatic) was verified for
neonatal urine. Furthermore, we report on neonatal urin-
ary creatinine values using IDMS-traceable methods.
Methods
Clinical procedure and sampling
Urine samples used in this study were initially collected
as part of recently reported studies on paracetamol or
propylene glycol disposition (propylene glycol containing
formulations for intravenous paracetamol, digoxin,
phenobarbital, or diphantoine administration) in neo-
nates [11,12]. For both studies, neonates were consid-
ered for inclusion after approval of these studies
(EUdraCT 2009-011243-39 and B-32220084836 respect-
ively) by the Ethics Board of the University Hospitals
Leuven, Belgium and following informed written paren-
tal consent. To further reduce the burden, urine collec-
tion was only performed in neonates in whom an
urinary bladder catheter was already present for clinical
indications. After a 6 h time interval, the urine was col-
lected and the volume was recorded. Subsequently, a
sample was stored at −20°C until analysis. Clinical char-
acteristics (birth weight, current weight, postnatal age,
gestational age) were recorded at the day of sample
collection.
Bio-analysis
Samples were analysed by a Jaffe and an enzymatic
method, applying the clinical available analytic methods
currently available in the University Hospitals Leuven
(Roche Diagnostics Jaffe (urine application without com-
pensation factor and a sample dilution factor of 1:25)
and enzymatic method (dilution factor of 1:50), both
IDMS traceable, measured on a Cobas c702 module)
[13,14]. Total imprecision (expressed as CV) of the Jaffe
assay determined according to CLSI EP5 was 2.2% at
61.5 mg/dL and 2.2% at 138.9 mg/dL with a measuring
range from 4.2 to 622 mg/dL. For the enzymatic assay,
total imprecision was 1.4% at 64.8 mg/dL and 1.2% at
145.8 mg/dL with a measuring range from 1.1 to
610 mg/dL. Internal quality control (iQC) was per-
formed with commercial control material (Biorad unas-
sayed) using simplified Westgard rules for statistical
process control and biological critical acceptance limits
[15]. As external quality control (eQC) the Biorad Unity
urine chemistry report was used. This system allows
comparison of our iQC results with values determined
in other laboratories using the same method, analyzer
and QC lot. We used a difference of more than 2 stand-
ard deviations of our mean from the peer group mean as
acceptance criterion. For plasma creatinine, we also par-
ticipated in the mandatory eQC scheme of the Belgian
National Scientific Institute of Public Health. At the time
of measurement of the study samples, there were no
problems with iQC as well as eQC results.
Statistics
Clinical characteristics and analytical results were de-
scribed by median and range, mean and standard de-
viation, or incidence. Passing-Beblok regression and
Bland-Altman were performed to explore the difference
between both measurements and trends in its variability.
Paired analysis (Wilcoxon) was performed to quantify
differences between both analyses, and covariates of dif-
ferences were explored (Rank correlation, multiple linear
regression). A p-value < 0.05 was considered statistically
significant (MedCalc®, Mariakerke, Belgium). Clinical
relevance was evaluated by using desirable biological cri-
teria for creatinine concentration (24 h) for bias (8.6%),
imprecision (12.0%) and total error allowable (TEa)
(28.4%) [15].
Results
Eighty-four urine samples were available for analysis.
These samples were collected in two cohorts of 23 neo-
nates each who had a median gestational age of 35 (range
24–41) weeks, had a postnatal age of 5 (range 1–26) days,
while birth weight was 2 680 (605–4 300) g and weight at
inclusion 2 640 (605–4 300) g. The median urine volume
(mL/6 h) was 58 (range 5.5-304) mL, equal to 3.7 (range
0.6-11.8) mL/kg/h.
Median IDMS traceable Jaffe urine creatinine was 9.3
(range 3.7 - 42.2) mg/dL, and median IDMS traceable en-
zymatic urine creatinine was 9.1 (range 3.8 - 42.9) mg/dL,
resulting in a median difference (Jaffe – enzymatic) of 0.1
(SD 0.6, range −2.4 to 1.00) mg/dL (p <0.001). A signifi-
cant Passing-Bablok regression between both creatinine
measurements was documented (y = 0.28 + 0.95 ×, 95% CI
slope 0.93-0.98, 95% CI intercept 0.12-0.48)) (Figure 1).
Bland-Altman further illustrates the mean difference
(0.2 mg/dL, equal to 0.4%), but also illustrates that there is
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a creatinine concentration related impact on both the
direction and the magnitude of the difference between
both measurements (Figure 2). Finally, there are also sig-
nificant correlations between the urinary creatinine con-
centrations and some indicators of maturation (age), most
significant for postnatal age (enzymatic method, r = −0.59,
95% CI −0.72 to −0.43, p < 0.001, Figure 3). There were no
significant differences between urinary samples from pre-
term compared to term neonates.
In a multiple regression model, urinary creatinine con-
centration and postnatal age remained independent vari-
ables of the difference between both assays, resulting in
a r [2] adjusted value of 0.45 (p < 0.001) (coefficients of
the regression equation: constant = −0.2147, creatinine
0.04508 and postnatal age −0.01966 respectively).
Discussion
Paired measurement of urinary creatinine in neonates
based on Jaffe and enzymatic IDMS-traceable assays re-
sulted in a limited mean difference of 0.2 mg/dL. Our
regression curve shows that enzymatic measurements
are proportionately 4.96% higher than Jaffe measure-
ments. This is well within the predefined biological cri-
teria. All individual paired results were within TEa. As
proportionately higher enzymatic values (within bio-
logical criteria) were also observed in a method compari-
son experiment (part of the method validation) using
random urine samples from adults, this is probably to a
large extent caused by a calibration difference. Our study
(and also the method validation), however, gives a snap-
shot of the difference between methods using specific
lots of calibrators and reagents. A new comparison using
different lots might yield slightly different results. Based
on our results Jaffe values are higher than enzymatic at
lower creatinine concentrations. This could in part be
explained by a constant positive interference in the Jaffe
assay (urinary amino acids, glucose, bilirubin, pseudo-
creatinines) as no compensation factor is used. In this
context, the independent significant effect of PNA on
the difference can probably also in part be explained by
urinary matrix variation with age and consequential vari-
ation in interference with predominantly the Jaffe assay.
A limitation of our study is that we did not use direct
comparison to a gold standard method to further exam-
ine the difference. The manufacturer, however, states
traceability to a gold standard method in the insert.
The overall lower creatinine synthesis and clearance
capacity in neonates is reflected in a lower urinary
Figure 1 Passing-Beblok (y = 0.28 + 0.95 ×, 95% CI slope 0.93-0.98, 95% CI intercept 0.12-0.48) between enzymatic and Jaffe creatinine
measurements (both mg/dL). (X-axis = creatinine in urine enzymatic, CreaU-enz, mg/dL; Y-axis = creatinine in urine Jaffe, Crea Jaffe U, mg/dL).
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creatinine concentration These values are indeed signifi-
cantly lower (5–20 fold) when compared to values re-
ported in children or adults [3-5,10]. Taking into
account these low concentrations and the exponential
increase of the CV at these low levels, the determined
difference is remarkably low. In a publication of Srivas-
tava et al. (comparing a Jaffe with an enzymatic assay,
both non-IDMS traceable), differences up to 80% for
creatinine urine values in urine samples of 18 children
have been reported [3]. For our study, the maximum
Figure 3 A significant inverse correlation (r = − 0.59, 95% CI - 0.72 to - 0.43, p < 0.001) between postnatal age (days) and urinary creatinine
concentration (enzymatic method, mg/dL) is documented, likely in part reflecting the oliguria and the associated higher urinary creatinine
concentrations in early neonatal compared to late neonatal life. (X-axis = postnatal age (days, PNA); Y-axis = creatinine in urine, enzymatic, mg/dL).
Figure 2 Bland Altman plot illustrates a mean difference of 0.2 mg/dL, equal to 0.4% in creatinine concentration measured. There is
also an impact of the creatinine concentration on the direction and extent of this difference between both assays. A higher creatinine urine
concentration (>25 mg/dL) results in a higher enzymatic compared to a Jaffe assay, while the reverse is true in lower urine concentrations
(<10 mg/dL) (X-axis = mean of all, mg/dL; Y-axis = difference [creatine in urine, Jaffe – creatinine in urine, enzymatic/mean of all]).
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observed difference was 12%, documented at the lowest
creatinine concentrations (Figure 2).
Conclusions
The tested IDMS-traceable assays showed interchangeable
in heterogeneous neonatal urine samples. Using these as-
says, neonatal urinary creatinine showed 5–20 fold lower
values than those observed in children or adults with a
significant negative correlation with postnatal age.
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